RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:23 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: RECURRENT LOW GRADE FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC